In conclusion, higher levels of miR-21 and miR-10b were present in the serum of patients with M0 and M1 HER2+ breast cancer, respectively, compared with stage-matched patients with HER2− breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.